Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Healthcare company (Biotechnology) with a market capitalization of $828M. The Maz Rating grades it against the other companies in its sector.
Syndax Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.20, Syndax Pharmaceuticals, Inc. trades at 2.9x sales. Over the last twelve months it generated about $285M of revenue and a net loss of $210M. It runs a gross margin of 93.7%, an operating margin of -61.7% and a net margin of -72.4%. It shows return on equity of -804.4%, return on invested capital of -31.2% and a free cash flow yield of -21.4%. On the balance sheet: a debt-to-equity ratio of -34.31 and a current ratio of 4.69. Over the past 52 weeks the share price ranged from $9.03 to $25.59, with a beta of 0.37.
Syndax Pharmaceuticals, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 20 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.